Mital Jhaveri: What New Data Reveal About DOACs and Androgen Receptor Inhibitors?
Mital Jhaveri, Clinical Anticoagulation, Heart Failure Pharmacist at NYC HHC Queens Hospital Center, shared on LinkedIn about a recent article by Mary Beth Nierengarten, published in Cancer, adding:
”Drug Interactions in Focus: What New Data Reveal About DOACs and Androgen Receptor Inhibitors
Managing anticoagulation in cancer patients can be complex, particularly due to potential drug-drug interactions that may heighten bleeding or thrombotic risks.
A recent study published in Cancer examined 2,997 patients with prostate cancer who were receiving direct oral anticoagulants (DOACs) in conjunction with androgen receptor pathway inhibitors, including enzalutamide, apalutamide, or abiraterone.
Key findings include:
- No significant increase in thrombosis risk when using enzalutamide or apalutamide alongside DOACs.
- No significant increase in bleeding risk with abiraterone combined with DOACs.
- Real-world evidence supports the safe co-administration of these therapies in appropriately selected patients.
These findings offer valuable reassurance for clinicians making anticoagulation decisions for patients undergoing modern prostate cancer treatments.
They also underscore the importance of considering real-world outcomes alongside theoretical pharmacokinetic concerns.”
Title: New standard of care for patients with asymptomatic brain metastases from melanoma
Author: Mary Beth Nierengarten
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 2, 2026, 15:28Kabilan K. L.: Management and Diagnosis of Acute Coronary Syndrome Types
-
Jun 2, 2026, 15:22Dhananjaya Kotebagilu Narayana Vamyanmane: High-Resolution Ultrasound Evaluation of Bowel Wall Ischemia
-
Jun 2, 2026, 15:20Joep Schellens: Influence of Dexamethasone and Tocilizumab on Fibrinolysis in COVID-19
-
Jun 2, 2026, 15:12Ebrahim Umer: The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
-
Jun 2, 2026, 15:10Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
-
Jun 2, 2026, 15:07Sayan Koley: Coagulation Science – Where Precision Saves Lives
-
Jun 2, 2026, 15:04Ahmed Mohsen: Low CHA₂DS₂-VA Score Does Not Always Mean No Anticoagulation
-
Jun 2, 2026, 15:04The Risk Factors and Optimal Prevention Strategies of VTE in Sickle Cell Disease – RPTH Journal
-
Jun 2, 2026, 14:26PNH and Thrombosis: From Pathogenesis to Complement Inhibition